Boston Scientific has launched its WaveWriter Alpha line of Spinal Cord Stimulator (SCS) Systems in Europe.
The portfolio includes four MRI conditional and Bluetooth-enabled implantable pulse generators (IPGs).
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
They are designed to provide enhanced personalisation based on patient needs, including rechargeable and non-rechargeable options, and access to waveforms that can cover multiple areas of pain.
SCS therapies deliver pulses of mild electric current to the spinal cord and break off pain signals sent to the brain to provide pain relief.
The CE-marked WaveWriter Alpha SCS Systems support the management of chronic intractable pain. Additionally, they are approved for peripheral nerve stimulation of the trunk for pain management.
Chronic pain refers to continuous and long-term pain, lasting more than 12 weeks. It is estimated to affect nearly 100 million people across Europe.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBoston Scientific Neuromodulation senior vice-president and president Maulik Nanavaty said: “The launch of the WaveWriter Alpha SCS Systems in Europe represents a significant step forward in the treatment of chronic pain.
“By unifying our portfolio of SCS devices and offering the latest therapy advances, we remain committed to advancing meaningful innovation, providing both physicians and patients access to the full benefits of our entire portfolio of devices.”
The SCS systems feature combination therapy. It is the only SCS portfolio that can offer layer paraesthesia and paraesthesia-free options simultaneously, the company said.
Furthermore, these systems support up to 32 contacts that target specific nerves along the spinal cord to meet the personal pain relief coverage needs of the individual patient.
The COMBO randomised control trial, which assessed the effectiveness of SCS compared to conventional SCS, found that the system offers 50% or greater pain relief in patients with chronic pain.
Multiple Level 1 RCTs and real-world studies support the design of the SCS therapy, the company noted.
Last week, Boston Scientific announced the limited launch of the enhanced ACURATE neo2 aortic valve system in Europe.
